Welcome to LookChem.com Sign In|Join Free

Hubei Vanz Pharm Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
5th
years
Home>>Products>>99% Temozolomide Powder

Product Certification&
Enterprise Certification

More Detail

Hubei Vanz Pharm Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Ms.Chelsea gao

Tel: 86-27-84492310

Ms.Bella Li

Tel: 008618986076206

Ms.Chelsea Gao

Tel: +86 27 84492310

Ms.Wendy

Tel: WhatsApp +8615927784577

Ms.Mirriam

Tel: +8618071739296

Mobile:

Tel: 86-27-84492310

Fax: 86-27-84402310

URL: http://www.vanzpharm.com/en/index.html

Province/state: Hubei

City: JIAYU

Street: FANHU INDUSTRY PARK

MaxCard:


    x
  • Ms.Bella Li
  • Ms.Chelsea Gao
Contact Suppliers

99% Temozolomide Powder

CAS NO.104987-11-3

  • Min.Order: 10 Gram
  • Payment Terms: L/C,T/T,MoneyGram
Contact Supplier

Product Details

Keywords

  • Temozolomide
  • Temozolomide 99%
  • 99% Temozolomide

Quick Details

  • ProName: 99% Temozolomide Powder
  • CasNo: 104987-11-3
  • Molecular Formula: C6H6N6O2
  • Appearance: white
  • Application: anti cancer
  • DeliveryTime: 7-10 days
  • PackAge: drum
  • Port: Shanghai/Wuhan
  • ProductionCapacity: 1000 Kilogram/Day
  • Purity: 99
  • Storage: room
  • LimitNum: 10 Gram

Superiority

99% Temozolomide Powder 

 Product Name:    Temozolomide
CAS:    85622-93-1
MF:    C6H6N6O2
MW:    194.15
EINECS:    630-358-9

 

Details

 Product Name:    Temozolomide
CAS:    85622-93-1
MF:    C6H6N6O2
MW:    194.15
EINECS:    630-358-9 

What is Temozolomide
Temozolomide is the first orally effective imidazotetrazine antitumor drug, which belongs to the second generation of alkylating agents with antitumor activity. It does not require intrahepatic metabolic activation after oral administration. It has good properties and does not have superimposed toxicity with other drugs, and has synergistic efficacy with radiotherapy. It is suitable for malignant gliomas that recur after conventional treatment, such as glioblastoma multiforme or degenerative astrocytoma, and also for the treatment of metastatic gliomas. First-line treatment for melanoma.

Temozolomide has been shown to be effective in some of the most common glioblastomas by basic and clinical studies, and its effect on glioblastoma multiforme has been more recognized in Europe.